Table 3.

Clinical trial summary of CAR-T cells with additional function proteins

NCT number	Target antigen	Gene-delivery proteins	Expression pattern of cargo	Tumor	Clinical stage	Status	Locations	Result
NCT04377932	GPC3	IL-15	unknown	liver cancer	phase 1	recruiting	Texas Children’s Hospital, Houston, Texas, USA	Steffin et al.19
NCT05103631	GPC3	IL-15	unknown	liver cancer	phase 1	recruiting	Houston Methodist Hospital, Houston, Texas, United States	Steffin et al.19
NCT03721068	GD2	IL-15	unknown	neuroblastoma, osteosarcoma	phase 1	recruiting	Emory Winship Cancer Institute, Atlanta, Georgia, USA Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA	unknown
NCT04715191	GPC3	IL-15,IL-21	unknown	liver cancer	phase 1	not yet recruiting	Texas Children’s Hospital, Houston, Texas, USA	unknown
NCT02932956	GPC3	IL-15, IL-21	unknown	liver cancer	phase 1	active, not recruiting	Texas Children’s Hospital, Houston, Texas, USA	unknown
NCT03778346	BCMA	IL-7 and CCL19	unknown	relapsed/refractory multiple myeloma	phase 1	unknown	The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China	Duan et al.32
NCT03929107	CD19	IL-7 and CCL19	unknown	B cell lymphoma	phase 2	unknown status	The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China	Lei et al.33
NCT04833504	CD19	IL-7 and CCL19	unknown	relapsed/refractory B cell lymphoma		completed	Second Affiliated Hospital, School of Medicine, Zhejiang University	Lei et al.33
NCT05659628	CD19	IL-7 and CCL19	unknown	diffuse large B cell lymphoma	phase 1	recruiting	The Second Affiliated Hospital of Zhejiang University, Ningbo First Hospital, Hangzhou, Zhejiang, China	unknown
NCT03198546	GPC3	IL-7 and CCL19	unknown	liver cancer	phase 1	recruiting	The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China	Pang et al.34
NCT02498912	MUC6ecto	IL-12	constitutive	ovarian, primary peritoneal, fallopian tube carcinoma	phase 1	active, not recruiting	Memorial Sloan Kettering Cancer Center New York, New York, USA	O’Cearbhaill et al.43
NCT03542799	EGFR	IL-12	inducible	metastatic colorectal cancer	phase 1	unknown	Shenzhen Second People’s Hospital, Shenzhen, Guangdong, China	unknown
NCT04684563	CD19	IL-18	constitutive	non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia	phase 1	recruiting	University of Pennsylvania, Philadelphia, Pennsylvania, USA	Svoboda et al.47
NCT04099797	GD2	C7R	unknown	high-grade glioma, diffuse intrinsic pontine glioma, medulloblastoma or other rare brain cancer that expresses GD2	phase 1	recruiting	Texas Children’s Hospital, Houston, Texas, USA	unknown
NCT03635632	GD2	C7R	unknown	neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2	phase 1	recruiting	Houston Methodist Hospital, Houston, Texas, USA Texas Children’s Hospital, Houston, Texas, USA	unknown
NCT05665062	CD19	orthogonal IL-2Rβ	unknown	hematological malignancies	phase 1	recruiting	City of Hope, Duarte, California, USA Roswell Park, Buffalo, New York, USA Columbia University Irving Medical Center, New York, New York, USA Memorial Sloan Kettering Cancer Center, New York, New York, USA Cleveland Clinic, Cleveland, Ohio, USA	unknown
NCT04556669	CD22	anti-PD-L1 scFv	unknown	cervical cancer, sarcoma, non small cell lung cancer	phase 1	recruiting	Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China	unknown
NCT03615313	MSLN	PD-1 antibody	unknown	mesothelin-positive advanced solid tumors	phase 1/2	unknown	Shanghai Cell Therapy Research Institute, Shanghai, China	unknown
NCT03030001	MSLN	PD-1 antibody	unknown	mesothelin-positive advanced solid tumors	phase 1/2	unknown	Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China	unknown
NCT02873390	EGFR	PD-1 antibody	unknown	EGFR family member positive advanced solid tumor	phase 1/2	unknown	Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China	unknown
NCT02862028	EGFR	PD-1 antibody	unknown	lung, liver and stomach cancers	phase 1/2	unknown	Shanghai International Medical Center, Shanghai, Shanghai, China	unknown
NCT03182816	EGFR	CTLA-4 and PD-1 antibody	unknown	EGFR-positive advanced solid tumors	phase 1/2	unknown	Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China	unknown
NCT03182803	MSLN	CTLA-4 and PD-1 antibody	unknown	mesothelin-positive advanced solid tumors	phase 1/2	unknown	Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China	unknown
NCT03179007	MUC1	CTLA-4 and PD-1 antibody	unknown	MUC1-positive advanced solid tumors	phase 1/2	unknown	Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China	unknown

All clinical trials were downloaded at www.clinicaltrials.gov (access date: August 10, 2023).